Differential susceptibility of several drug-resistant strains of herpes simplex virus type 2 to various antiviral compounds

Antiviral Chemistry and Chemotherapy

Volumn 8, Issue 5, 1997, Pages 457-461

  Andrei, G ^a   Snoeck, R ^a   De Clercq, E ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Acyclic nucleoside phosphonate; Acyclovir; Cidofovir; Herpes simplex virus; Resistance

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; ADEFOVIR; ANTIVIRUS AGENT; CIDOFOVIR; FIACITABINE; FOSCARNET; GANCICLOVIR; NUCLEOSIDE ANALOG; PENCICLOVIR; PHOSPHONOACETIC ACID; VIDARABINE;

ANIMAL CELL; CONTROLLED STUDY; CROSS RESISTANCE; DRUG RESISTANCE; HERPES SIMPLEX VIRUS 2; MUTATION; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; STRAIN DIFFERENCE; STRUCTURAL GENE; VERO CELL; VIRUS ISOLATION;

EID: 0030921143     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029700800509     Document Type: Short Survey

References (18)

1. Andrei G, Snoeck R & De Clercq E (1995) Susceptibilities of several drug-resistant herpes simplex virus type 1 strains to alternative antiviral compounds. Antimicrobial Agents and Chemotherapy 39: 1632-1635.
2. Coen DM (1996) Nucleosides and foscarnet. Mechanisms. In Antiviral Drug Resistance. Edited by DD Richman. Chichester: John Wiley & Sons, pp. 81-102.
3. Collins P & Darby G (1991) Laboratory studies of herpes simplex virus strains resistant to acyclovir. Reviews in Medical Virology 1: 19-28.
4. Crumpacker CS, Schnipper LE, Marlowe SI, Kowalsky PN, Hershey BJ & Levin MJ (1982) Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. New England Journal of Medicine 306: 343-346.
5. Eriksson B, Larsson A, Helgstrand E, Johansson NG & Öberg B (1980) Pyrophosphate analogues as inhibitors of herpes simplex type 1 DNA polymerase. Biochimica et Biophysica Acta 607: 53-64.
6. Erlich KS, Mills J, Chatis P, Mertz GJ, Busch DF, Follansbee SE, Grant RM & Crumpacker CS (1989) Acyclovir-resistant herpes simplex virus infections in patients with the acquired immuno deficiency syndrome. New England Journal of Medicine 302: 293-296.
7. Field AK & Biron KK (1994) 'The end of innocence' revisited: resistance of herpesviruses to antiviral drugs. Clinical Microbiological Reviews 7: 1-13.
8. Lalezari JP, Drew WL, Glutzer E, Miner D, Safrin S, Owen Jr WF, Davidson JM, Fisher PE & Jaffe HS (1994) Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)-propyl]cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS. Journal of Infectious Diseases 170: 570-572.
9. Lalezari JP, Stagg RJ, Kuppermann BD, Holland GN, Kramer F, Ives DV, Youle M, Robinson MR, Drew WL & Jaffe HS (1997) Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Annals of Internal Medicine 126: 257-263.
10. Mendel DB, Barkhimer DB, Kern ER & Chen MS (1995) Isolation and initial characterization of a herpes simplex virus type 2 (HSV-2) strain with decreased sensitivity to cidofovir. Antiviral Research 26: A312.
11. Naesens L, Snoeck R, Andrei G, Balzarini J, Neyts J & De Clercq E (1997) HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antiviral Chemistry and Chemotherapy 8: 1-23.
12. Safrin S, Assaykeen T, Follansbee S & Mills J (1990) Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. Journal of Infectious Diseases 161: 1078-1084.
13. Safrin S, Crumpacker CS, Chatis P, Davis R, Hafner R, Rush J, Kessler HA, Landry B & Mills J (1991) A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. New England Journal of Medicine 325: 551-555.
14. Safrin S, Kemmerly S, Plotkin B, Smith T, Weissbach N, De Veranez D, Phan LD & Cohn D (1994) Foscarnet-resistant herpes simplex virus infection in patients with AIDS. Journal of Infectious Diseases 169: 193-196.
15. Snoeck R, Andrei G, De Clercq E, Gerard M, Clumeck N, Tricot G & Sadzot-Delvaux C (1993) A new topical treatment for resistant herpes simplex infections. New England Journal of Medicine 329: 968-969.
16. Snoeck R, Andrei G, Gerard M, Silverman A, Hedderman A, Balzarini J, Sadzot-Delvaux C, Tricot G, Clumeck N & De Clercq E (1994) Successful treatment of progressive mucocutaneous infection due to acyclovir-and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine (HPMPC). Clinical Infectious Diseases 18: 570-578.
17. Snoeck R, Andrei G & De Clercq E (1996) Patterns of resistance and sensitivity to antiviral compounds of drug-resistant strains of human cytomegalovirus selected in vitro. European Journal of Clinical Microbiology and Infectious Diseases 15: 574-579.
18. Vinckier F, Boogaerts M, De Clerck D & De Clercq E (1987) Chronic herpetic infection in an immunocompromised patient: report of a case. Journal of Oral and Maxillofacial Surgery 45: 723-728.